Link to this page
Minimum PDDI Information Ontology
Last uploaded:
October 17, 2023
Jump to:
Id | http://purl.obolibrary.org/obo/MPIO_0000004
http://purl.obolibrary.org/obo/MPIO_0000004
|
---|---|
Preferred Name | suspected drug-drug interaction evidence |
Definitions |
An information content entity that provides support for or refutation of a drug-drug interaction statement.
|
Type | http://www.w3.org/2002/07/owl#Class |
All Properties
label | suspected drug-drug interaction evidence
|
---|---|
prefLabel | suspected drug-drug interaction evidence
|
prefixIRI | MPIO:0000004
|
textual definition | An information content entity that provides support for or refutation of a drug-drug interaction statement.
|
subClassOf | |
type | |
example of usage | "Both corticosteroids and aldosterone antagonists have been shown to substantially increase the risk of UGIB in patients on NSAIDs, with relative risks of 12.8 and 11 respectively compared to a risk of 4.3 with NSAIDs alone."
“Colestyramine and colestipol do not appear to have any clinically important effects on the absorption of aspirin.”
“A crossover study in 36 healthy subjects found that aspirin 325 mg daily for two doses had no effect on the pharmacokinetics of a single 80-mg dose of tapentadol”
|
MPIO user-centered definition | The support for or refutation of a drug-drug interaction in humans; it may be data resulting from clinical studies, clinical observation or physiological experiments, or it may be an extrapolation based on drug-drug interaction mechanisms.
|
Add comment
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |
- Problem retrieving properties: